Clinical trials: Influenza Viruses
Influenza
The Immunogenicity and Safety of 2013-2014 Seasonal Trivalent Influenza Vaccine
The purpose of this study is to evaluate the immunogenicity and safety of Northern hemisphere 2013-2014 seasonal trivalent inactivated influenza vaccine in 60 healthy infants aged 6-35 months old, 60 healthy adults aged 18-60…
- Trial name
- NCT02269852
- Testing
- trivalent seasonal influenza vaccine
- Where
- China
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Pandemic Influenza Disease
Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects
The present study, phase III, randomized, controlled, observer-blind, multicenter study, will evaluate safety, tolerability and immunogenicity of two doses of an adjuvanted monovalent influenza vaccine compared with an adjuvanted…
- Trial name
- NCT00841763
- Testing
- Trivalent influenza virus vaccine (TIV), Adjuvanted monovalent influenza virus vaccine (aH5N1), Adjuvanted trivalent influenza virus vaccine (aTIV)
- Where
- 2 sites in Finland, Germany
- Volunteers
- 3,647 people, healthy volunteers welcome
- Sponsor
- Novartis
Influenza, Human
Substance Balance Study of [14C]ZX-7101A in Healthy Adult Male Subjects in China
The objectives of this substance balance study in healthy Chinese adult male subjects are to obtain human radioactivity recovery data and major excretion pathways, and to obtain pharmacokinetics of total radioactivity in plasma…
- Trial name
- NCT05720091
- Testing
- ZX-7101A 80mg
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Nanjing Zenshine Pharmaceuticals
Influenza
Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV
The purpose of this study was to evaluate and compare the safety, reactogenicity, immunogenicity, relative efficacy and effectiveness of FluBlok to a licensed trivalent influenza vaccine (TIV)in healthy adults age 50-64 years.
- Trial name
- NCT00539864
- Testing
- FluBlok Influenza Vaccination, TIV (Fluzone) Influenza Vaccination
- Where
- 5 sites in United States
- Volunteers
- 602 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
Healthy, Influenza
Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults
The objective is to assess the safety of bivalent vaccine of two new 6:2 influenza virus reassortants in healthy adults prior to the release of the trivalent vaccine (FluMist) containing them.
- Trial name
- NCT00125944
- Testing
- FluMist
- Where
- 4 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers.
The present study will evaluate the concomitant administration of a Quadrivalent Inactivated Influenza Vaccine with the highest dose level of OVX836 (480µg) tested in the clinic to date, for which the likelihood for interference…
- Trial name
- NCT05284799
- Testing
- OVX836 480µg, Quadrivalent Inactivated Influenza Vaccine (Fluarix® Tetra)
- Where
- Australia
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Osivax
Seasonal Influenza
Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011, When Administered to Adult and Elderly Subjects
Influenza poses a significant threat to individual and public health, and influenza vaccination with a trivalent inactivated influenza vaccine is widely recommended to children, adults at risks and elderly.
- Trial name
- NCT01161264
- Testing
- Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011
- Where
- Germany
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
SARS-CoV-2, COVID-19
Clinical Evaluation of the VitaSIRO Solo™ Respiratory Assay
The purpose of this clinical trial is to demonstrate the clinical performance of the VitaSIRO solo™ SARS-CoV-2/Flu/RSV Assay in detecting SARS-CoV-2, Flu A, Flu B and RSV in symptomatic population.
- Conditions
- SARS-CoV-2, COVID-19, RSV, Influenza
- Trial name
- NCT06689423
- Testing
- Credo POCT Device
- Where
- Taiwan
- Volunteers
- 1,268 people
- Sponsor
- Credo Diagnostics Biomedical Pte. Ltd.
Influenza Immunization (Healthy Volunteers)
Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24
This EPSS will determine the vaccinee reporting rates (RRs) of suspected ADRs following routine vaccination with VaxigripTetra® and Efluelda® respectively, during the NH influenza season 2023/24.
- Trial name
- NCT06059456
- Testing
- Quadrivalent Influenza Vaccine, High-Dose Quadrivalent Influenza Vaccine
- Where
- 11 sites in Finland, Germany
- Volunteers
- 2,078 people, healthy volunteers welcome
- Sponsor
- Sanofi
Mumps, Influenza
The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School Students
This study is a randomized, controlled, open-label phase Ⅳ clinical trial of a live attenuated mumps vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
- Trial name
- NCT06208683
- Testing
- Mumps vaccine, Live (MV), Influenza Vaccine, inactivated, quadrivlent(QIV)
- Where
- 3 sites in China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Influenza
A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Non-Elderly Adults and Elderly Subjects
This is an open study of the use of AdimFlu-V (2012-2013 season) vaccine in non-elderly and elderly subjects. All participates will receive one dose of vaccine (0.5 ml) by intramuscular injection into the upper arm.
- Trial name
- NCT01759654
- Testing
- AdimFlu-V
- Where
- Taiwan
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Adimmune Corporation
Influenza
Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults
This study is to assess the safety of a bivalent vaccine of two new 6:2 influenza virus reassortants in healthy adults prior to the release of the trivalent vaccine (FluMist) containing them.
- Trial name
- NCT00192127
- Testing
- FluMist
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
A Retrospective, Observational Registry of Participants With Avian Influenza Infection
This is a global, multi-center, observational registry of participants with suspected or confirmed infection with avian influenza A H5N1.
- Trial name
- NCT02743676
- Volunteers
- 648 people
- Sponsor
- Hoffmann-La Roche
Influenza
Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age
Primary Objective: To describe the safety of the 2004-2005 pediatric formulation of the inactivated, split-virion influenza vaccine Fluzone®, given in the two-dose schedule (described in the package insert for vaccine-naïve young…
- Trial name
- NCT00858468
- Testing
- Influenza virus vaccine (2004-2005 Formulation)
- Where
- 8 sites in United States
- Volunteers
- 394 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza (Pandemic)
A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant
This is a randomized, observer-blinded, placebo-controlled trial in adults 18 to 64 years old. Randomization will be stratified by age (18 to 49 years and 50 to 64 years) and by prior influenza immunization within the past three…
- Trial name
- NCT02078674
- Testing
- Monovalent Avian Influenza VLP (H7N9), Matrix-M1™ adjuvant
- Where
- 5 sites in United States
- Volunteers
- 610 people, healthy volunteers welcome
- Sponsor
- Novavax
Influenza, Common Cold
A Comparison of Solid and Soluble Forms of Cold and Influenza Remedies
The study is designed to investigate whether paracetamol from a hot remedy reaches the plasma faster than standard paracetamol tablets.
- Trial name
- NCT01332578
- Testing
- Paracetamol, Phenylephrine, Ascorbic Acid
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital
The purpose of this study is to determine whether zanamivir aqueous solution given by intravenous injection is safe in treating hospitalized patients with confirmed influenza infection.
- Trial name
- NCT01014988
- Testing
- zanamivir aqueous solution
- Where
- 110 sites in United States, Australia and 11 more
- Volunteers
- 202 people
- Sponsor
- GlaxoSmithKline
Respiratory Disorders
Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix Vaccine
This study will provide information regarding the sequential administration of two vaccines adjuvanted with AS01. The aim of this study is to understand immunogenicity and safety of NTHi-Mcat vaccine when administered…
- Trial name
- NCT03894969
- Testing
- GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E, Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A)
- Where
- 14 sites in Estonia, Finland and 3 more
- Volunteers
- 541 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Healthy Volunteers
Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older
VAM00001 is a Phase I/II, randomized, modified double-blind, multi-center study. The purpose of this study is to compare 2 dose levels of Panblok H7 (dose 1 and dose 2 of rHA) with a standard squalene dose of adjuvant MF59 to…
- Trial name
- NCT05608005
- Testing
- Panblok + MF59 Dose 1, Panblok + MF59 Dose 2, Unadjuvanted Panblok Dose 3
- Where
- 16 sites in United States
- Volunteers
- 581 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Healthy Participants
A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07)
The goal of this clinical study is to learn if giving repeated annual doses of MK-1406 (CD388) is safe and how the body reacts to it in healthy adults who have already received one dose without serious side effects.
- Trial name
- NAVIGATE-2 (NCT07225959)
- Testing
- MK-1406 Injection
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.